Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Researchers from University of Washington, Division of Oncology discuss findings in vaccines
January 15th, 2008
New investigation results, 'Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers,' are detailed in a study published in Clinical Immunology. "The ability of a cancer vaccine to elicit a specific measurable T-cell response is increasingly being used to prioritize immunization strategies for therapeutic development. Knowing the optimal time during a vaccine regimen to measure the development of tumor-specific immunity would greatly facilitate the assessment of T-cell responses," investigators in the United States report.
"The purpose of this study was to overview the kinetics of...
Source: Cancer Weekly (2008-01-15)
|
